Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Martin Dreyling,Franck Morschhauser,Krimo Bouabdallah,Dominique Bron,David Cunningham,Sarit Assouline,Gregor Verhoef,Kim Linton,Catherine Thieblemont,Umberto Vitolo,Florian Hiemeyer,M. Giurescu,J. Garcia-Vargas,Igor Gorbatchevsky,Li Liu,Karl Koechert,Carol Peña,M Neves,Barrett H. Childs,Pier Luigi Zinzani +19 more
TLDR
Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma.About:
This article is published in Annals of Oncology.The article was published on 2017-09-01 and is currently open access. It has received 202 citations till now. The article focuses on the topics: Copanlisib & Aggressive lymphoma.read more
Citations
More filters
Journal ArticleDOI
Targeting PI3K in cancer: mechanisms and advances in clinical trials
TL;DR: A critical review is performed to summarize the role of the PI3K pathway in tumor development, recentPI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3k inhibition.
Journal ArticleDOI
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A. Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Cupit,Li Liu,Karl Köchert,Henrik Seidel,Carol Peña,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +26 more
TL;DR: High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes, and this phase II study demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Journal ArticleDOI
AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
John P. Leonard,Marek Trneny,Koji Izutsu,Nathan Fowler,Xiaonan Hong,Jun Zhu,Huilai Zhang,Fritz Offner,Adriana Scheliga,Grzegorz S. Nowakowski,Antonio Pinto,Francesca Re,Laura Fogliatto,Phillip Scheinberg,Ian W. Flinn,Cláudia Moreira,José Cabeçadas,David Liu,Stacey Kalambakas,Pierre Fustier,Chengqing Wu,John G. Gribben +21 more
TL;DR: In this article, the authors report that indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy and at relapse, single-agent rituximab is commonly administered.
Journal ArticleDOI
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
Umberto Campia,Javid Moslehi,Laleh Amiri-Kordestani,Ana Barac,Joshua A. Beckman,David D. Chism,Paul Cohen,John D. Groarke,Joerg Herrmann,Carolyn M. Reilly,Neal L. Weintraub +10 more
TL;DR: Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors.
Journal ArticleDOI
Genetic alterations and their clinical implications in DLBCL
TL;DR: Application of next-generation sequencing technologies, especially whole-exome sequencing, has helped to define the genomic landscape of diffuse large B cell lymphoma (DLBCL), and characterization of genetic events provides important insights into the pathogenesis of DLBCL.
References
More filters
Journal ArticleDOI
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
TL;DR: The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.
Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps +10 more
TL;DR: The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
TL;DR: In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
Related Papers (5)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A. Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Cupit,Li Liu,Karl Köchert,Henrik Seidel,Carol Peña,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +26 more
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more